Can Breathing Pattern Assessment Predict the Need of Ventilatory Support in Treated Infants with Spinal Muscular Atrophy Type 1?

This publication has 10 references indexed in Scilit:

• Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
  The Lancet Neurology, 2021
• A new respiratory scoring system for evaluation of respiratory outcomes in children with spinal muscular atrophy type1 (SMA1) on SMN enhancing drugs
  Neuromuscular Disorders, 2021
• Risdiplam in Type 1 Spinal Muscular Atrophy
  New England Journal of Medicine, 2021
• Effect of Nusinersen on Respiratory Muscle Function in Different Subtypes of Type 1 Spinal Muscular Atrophy
  American Journal of Respiratory and Critical Care Medicine, 2019
• A New Method for Measuring Bell-Shaped Chest Induced by Impaired Ribcage Muscles in Spinal Muscular Atrophy Children
  Frontiers in Neurology, 2018
• Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics
  Neuromuscular Disorders, 2018
• Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
  New England Journal of Medicine, 2017
• Spontaneous Breathing Pattern as Respiratory Functional Outcome in Children with Spinal Muscular Atrophy (SMA)
  PLOS ONE, 2016
• Spinal Muscular Atrophies
  Pediatric Clinics of North America, 2015
• Reference ranges for respiratory rate measured by thermistry (12-84 months).
  Archives of Disease in Childhood, 1993